TY - JOUR T1 - Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data JF - medRxiv DO - 10.1101/2020.09.02.20186817 SP - 2020.09.02.20186817 AU - John Ojal AU - Samuel P. C. Brand AU - Vincent Were AU - Emelda A Okiro AU - Ivy K Kombe AU - Caroline Mburu AU - Rabia Aziza AU - Morris Ogero AU - Ambrose Agweyu AU - George M Warimwe AU - Sophie Uyoga AU - Ifedayo M O Adetifa AU - J Anthony G Scott AU - Edward Otieno AU - Lynette I Ochola-Oyier AU - Charles N Agoti AU - Kadondi Kasera AU - Patrick Amoth AU - Mercy Mwangangi AU - Rashid Aman AU - Wangari Ng’ang’a AU - Benjamin Tsofa AU - Philip Bejon AU - Edwine Barasa AU - Matt. J. Keeling AU - D. James. Nokes Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186817.abstract N2 - Policy makers in Africa need robust estimates of the current and future spread of SARS-CoV-2. Data suitable for this purpose are scant. We used national surveillance PCR test, serological survey and mobility data to develop and fit a county-specific transmission model for Kenya. We estimate that the SARS-CoV-2 pandemic peaked before the end of July 2020 in the major urban counties, with 34 - 41% of residents infected, and will peak elsewhere in the country within 2-3 months. Despite this penetration, reported severe cases and deaths are low. Our analysis suggests the COVID-19 disease burden in Kenya may be far less than initially feared. A similar scenario across sub-Saharan Africa would have implications for balancing the consequences of restrictions with those of COVID-19.Competing Interest StatementDJN, VW are members of the National COVID-19 Modelling Technical Committee, for the Ministry of Health, Government of Kenya. KK, PA, MM, RA are from the Ministry of Health, Government of Kenya, and WN from the Presidential Policy & Strategy Unit, The Presidency, Government of Kenya. All other authors declare no competing interests.Funding StatementThis research was funded by: Department for International Development and Wellcome Trust [220985/Z/20/Z]; National Institute for Health Research (NIHR) (17/63/82) using UK aid from the UK Government to support global health research; Wellcome Trust Intermediate Fellowship awards [201866;107568] EAO, LIOO; MRC/DFID African Research Leader Fellowship (MR/S005293/1) IMOA, CM; NIHR Global Health Research Unit on Mucosal Pathogens (16/136/46) JO; DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1) AA; Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation JAGSAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research InstituteAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full Kenyan SARS-CoV-2 line list contains sensitive personal information that could potentially allow the identification of individual cases. The analysis performed in this study only required a highly aggregated dataset derived from the Kenyan linelist. Other data used in this paper was openly available. All data is available in the main text or the supplementary materials. The code base underlying the analysis is accessible at the open github repository https://github.com/ojal/KenyaSerology. https://github.com/ojal/KenyaSerology ER -